Color Genomics
-39%
est. 2Y upside i
Color provides the technology and infrastructure for large-scale health initiatives, from population genomics programs to high throughput COVID-19 testing.
Rank
#3622
Sector
HealthTech
Est. Liquidity
~3Y
Data Quality
Data: MediumColor Health operates in a large and growing HealthTech market, with a strong focus on virtual cancer care and genomics.
Last updated: March 10, 2026
Color successfully leverages its Virtual Cancer Clinic and AI partnerships (like Google Cloud and OpenAI) to capture significant market share in the rapidly growing population health and virtual cancer care segments, expanding its enterprise partnerships. Revenue accelerates to $500M+ by 2028, justifying an $8.05B+ valuation at a premium multiple, leading to a successful IPO.
Color maintains its position in precision genomics and steadily grows its virtual cancer clinic offerings through existing and new employer/health plan partnerships. Revenue grows moderately to ~$350M by 2028, leading to an acquisition or IPO at a $5.29B valuation, offering modest returns to common shareholders.
Intense competition from incumbents and other well-funded genomics companies, coupled with regulatory hurdles and slower-than-expected adoption of virtual cancer care, limits Color's growth. Revenue stagnates around $250M, leading to a down round or an acquisition at a significantly reduced valuation of $2.76B, severely impacting common stock value due to liquidation preferences.
Preference Stack Risk
moderateFunding Intensity
11%Investors hold approximately $491 million in liquidation preferences ahead of common stockholders, representing 10.67% of the current $4.6B valuation.
Dilution Risk
moderateGiven the Series E in 2021 and the time elapsed, there is a moderate risk of further dilution if the company requires additional significant funding rounds before an exit.
Secondary Liquidity
limitedSecondary market activity is low, with few buyers or sellers, though platforms like Forge, EquityZen, Hiive, and Prospect offer limited avenues for accredited investors to buy/sell shares.
Other — 3 roles
- About this role · Remote, USA
- Careers · Select an option
- careers@color.com · Remote, USA
Last updated: February 22, 2026
Questions to Ask at the Interview
Strategic questions based on Color Genomics's data — designed to show you've done your homework.
- 1
“How does Color Health plan to differentiate its Virtual Cancer Clinic offerings and AI capabilities to fend off potential expansion from large healthcare incumbents like UnitedHealth or CVS Health, especially given the high competitive intensity in the broader health tech market?”
- 2
“With the reported pivot away from COVID-19 testing and associated layoffs, what is the company's updated strategy for achieving significant revenue acceleration beyond the current ~17% YoY growth, particularly in the next 2-3 years?”
- 3
“Given the Series E funding round in late 2021, what is the anticipated timeline and strategic path for a liquidity event (e.g., IPO or acquisition), and how does the company plan to ensure meaningful returns for common stock holders amidst the current valuation and preference stack?”
Community
Valuation Sentiment
Our model estimates -39% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.